The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

AC1L3TRG     (1-hydroxy-1-phosphonooxy...

Synonyms: 186Re Hedp, 140709-07-5, rhenium-186 HEDP
This record was replaced with 121983.
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of (1-hydroxy-1-phosphonooxy-ethoxy)phosphonic acid

 

High impact information on (1-hydroxy-1-phosphonooxy-ethoxy)phosphonic acid

 

Chemical compound and disease context of (1-hydroxy-1-phosphonooxy-ethoxy)phosphonic acid

 

Biological context of (1-hydroxy-1-phosphonooxy-ethoxy)phosphonic acid

 

Anatomical context of (1-hydroxy-1-phosphonooxy-ethoxy)phosphonic acid

  • Two patients who received 3515 MBq 186Re-HEDP showed grade 3 toxicity (thrombocytes 25-50 x 10(9)/l), defined as unacceptable toxicity [8].
  • The thorough clinical and laboratory investigation of both patients assessed that this extraosseous radio-rhenium accumulation was multifactorial with the main cause being a disturbance of body fluid acid-balance, favoring calcium and phosphate ion precipitation and leading to 186Re-HEDP extraosseous uptake [10].
 

Associations of (1-hydroxy-1-phosphonooxy-ethoxy)phosphonic acid with other chemical compounds

 

Analytical, diagnostic and therapeutic context of (1-hydroxy-1-phosphonooxy-ethoxy)phosphonic acid

  • Scintigraphic images in rabbits after injecting 70-100 MBq of 186Re-CTMP and using a dual head gamma camera were observed to be superior to 186Re-HEDP, prepared by a procedure standardized by us [11].
  • Patients described an improvement on Karnofsky performance status (KPS) from 73 +/- 7 percent to 85 +/- 8 percent 12 weeks after 188Re-HEDP (p < 0. 05), from 72 +/- 13 percent to 79 +/- 12 percent after 186Re-HEDP (p = 0.251), and from 62 +/- 14 percent to 69 +/- 16 percent after 89Sr (p = 0.415) [12].

References

  1. Phase 1 study of rhenium-186-HEDP in patients with bone metastases originating from breast cancer. de Klerk, J.M., van het Schip, A.D., Zonnenberg, B.A., van Dijk, A., Quirijnen, J.M., Blijham, G.H., van Rijk, P.P. J. Nucl. Med. (1996) [Pubmed]
  2. Transient cranial neuropathy in prostatic cancer with bone metastases after rhenium-186-HEDP treatment. de Klerk, J.M., Zonnenberg, B.A., Krouwer, H.G., Blijham, G.H., van Dijk, A., van het Schip, A.D., van Die, J., van Rijk, P.P. J. Nucl. Med. (1996) [Pubmed]
  3. Evaluation of thrombocytopenia in patients treated with rhenium-186-HEDP: guidelines for individual dosage recommendations. de Klerk, J.M., van het Schip, A.D., Zonnenberg, B.A., van Dijk, A., Stokkel, M.P., Han, S.H., Blijham, G.H., van Rijk, P.P. J. Nucl. Med. (1994) [Pubmed]
  4. Bone marrow absorbed dose of rhenium-186-HEDP and the relationship with decreased platelet counts. de Klerk, J.M., van Dieren, E.B., van het Schip, A.D., Hoekstra, A., Zonnenberg, B.A., van Dijk, A., Rutgers, D.H., Blijham, G.H., van Rijk, P.P. J. Nucl. Med. (1996) [Pubmed]
  5. Pharmacokinetics of rhenium-186 after administration of rhenium-186-HEDP to patients with bone metastases. de Klerk, J.M., van Dijk, A., van het Schip, A.D., Zonnenberg, B.A., van Rijk, P.P. J. Nucl. Med. (1992) [Pubmed]
  6. Nuclear medicine in diagnosis and therapy of bone and joint diseases. Riccabona, G. Nuclear medicine review. Central & Eastern Europe : journal of Bulgarian, Czech, Macedonian, Polish, Romanian, Russian, Slovak, Yugoslav societies of nuclear medicine and Ukrainian Society of Radiology. (1999) [Pubmed]
  7. Serum Hemoglobin Levels Predict Response to Strontium-89 and Rhenium-186-HEDP Radionuclide Treatment for Painful Osseous Metastases in Prostate Cancer. van der Poel, H.G., Antonini, N., Hoefnagel, C.A., Horenblas, S., Valdes Olmos, R.A. Urologia internationalis. (2006) [Pubmed]
  8. Dose escalation study of rhenium-186 hydroxyethylidene diphosphonate in patients with metastatic prostate cancer. de Klerk, J.M., Zonnenberg, B.A., van het Schip, A.D., van Dijk, A., Han, S.H., Quirijnen, J.M., Blijham, G.H., van Rijk, P.P. European journal of nuclear medicine. (1994) [Pubmed]
  9. Rhenium-186-HEDP palliative treatment in disseminated bone metastases due to prostate cancer. Limouris, G., Shukla, S.K., Manetou, A., Kouvaris, I., Plataniotis, G., Triantafyllou, N., Rigas, A.V., Vlahos, L. Anticancer Res. (1997) [Pubmed]
  10. Gastric uptake during Re-186 HEDP bone scintigraphy. Limouris, G.S., Skukla, S.K. Anticancer Res. (1997) [Pubmed]
  11. 186Re-1,4,8,11-tetraaza cyclotetradecyl-1,4,8,11-tetramethylene phosphonic acid: a novel agent for possible use in metastatic bone-pain palliation. Kothari, K., Samuel, G., Banerjee, S., Unni, P.R., Sarma, H.D., Chaudhari, P.R., Unnikrishnan, T.P., Pillai, M.R. Nucl. Med. Biol. (2001) [Pubmed]
  12. Systemic radionuclide therapy in pain palliation. Liepe, K., Runge, R., Kotzerke, J. The American journal of hospice & palliative care. (2005) [Pubmed]
 
WikiGenes - Universities